Search Results
Jan 08, 2026, 00:01 ET Biopharma's Innovation Engine Powers Ahead, but Its Business Model Faces Mounting Strain
high unmet need, such as GLP-1s for obesity and monoclonal antibodies for Alzheimer's. This can lead to a kind of herd mentality in pipeline decision making. For example, there are more than 100 obesity compounds in the industry pipeline, and more than 35 have a GLP-1 component.M&A
More news about: Boston Consulting Group (BCG)
Jan 07, 2026, 11:44 ET Robard Launches Biocare2™
Appetite Returns and Metabolism Shifts After Stopping GLP-1 UseMOUNT LAUREL, N.J., Jan. 7, 2026 /PRNewswire/ -- As individuals move beyond GLP-1 use, a new challenge has emerged: supporting nutrition
More news about: Robard Corporation
Jan 07, 2026, 11:16 ET Ochsner Connected Health and Crux launch partnership to make obesity management medicine accessible and affordable for employers nationwide
comprehensive, and cost-effective GLP-1 benefit that helps members achieve their healthy weight goals while enhancing workplace health and engagement."Employers are struggling to balance the potentially vast clinical impact of GLP-1 medications with the cost to provide them,"
More news about: Ochsner Digital Medicine
Jan 07, 2026, 09:04 ET WHAT'S HOT AT WINTER FANCYFAIRE 2026: KANZEN MEAL®'S NUTRIENT DENSE FROZEN MEALS
Von's.Emerging as a top 'GLP-1 friendly' brand. According to recent Kantar data*, GLP-1 users are a significant
More news about: KANZEN MEAL
Jan 07, 2026, 07:05 ET Fitness Ventures Leads the 2026 New Year's Rush as Strength Training Becomes the Foundation of Modern Fitness
awareness of its role in metabolism, mobility, bone health, and injury prevention. This shift is further reinforced by the growing use of GLP-1 medications, where experts emphasize the importance of maintaining lean muscle and overall strength as part of a balanced fitness routine. While
More news about: FITNESS VENTURES
Jan 07, 2026, 07:00 ET Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
"As we continue to advance our promising portfolio of metabolic therapies, including VK2735, our potentially best-in-class GLP-1/GIP dual agonist in Phase 3 trials for obesity, we are also building the appropriate commercial capabilities to maximize the opportunities ahead.
More news about: Viking Therapeutics, Inc.
Jan 07, 2026, 06:30 ET Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Upcoming MilestonesAnnounced that IMU-856 demonstrated a dose-dependent increase of endogenous glucagon-like peptide-1 (GLP-1) levels in a post hoc analysis of patients from the phase 1b clinical trial in celiac disease. IMU-856 also showed a dose-dependent reduction
More news about: Immunic, Inc.
Jan 06, 2026, 12:29 ET EMED PROVIDES ACCESS TO FDA-APPROVED WEGOVY® PILL THROUGH ITS TRUSTED, CLINICALLY GUIDED MODEL OF CARE
leading digital health platform for GLP-1/GIP population health management, today announced it has been named a Novocare Recognized Care Provider delivering access to the newly FDA-approved Wegovy® pill, the first and only oral GLP-1 medication approved for chronic weight
More news about: eMed Population Health
Jan 06, 2026, 03:19 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Orforglipron developed by Eli Lilly and Co | Obesity and T2DMA once-daily, oral small-molecule GLP-1 RA for managing overweight/obesity and T2DM, also under investigation for obstructive sleep apnea and hypertension in individuals with obesity.
More news about: Clarivate Plc
Jan 06, 2026, 03:07 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Orforglipron developed by Eli Lilly and Co | Obesity and T2DMA once-daily, oral small-molecule GLP-1 RA for managing overweight/obesity and T2DM, also under investigation for obstructive sleep apnea and hypertension in individuals with obesity.
More news about: Clarivate Plc
Jan 06, 2026, 01:49 ET CES 2026で見逃せないもの
1月6日、午前9時、ベネチアン、マルセロ4404女性のためのヘルステック設計：AIにおけるデフォルト男性の終焉（K'ept Health提供）1月6日、午前9時55分、ベネチアン、マルセロ4404GLP-1効果：女性が形づくるヘルスケアの未来（PwC提供） 1月6日、午前10時50分、ベネチアン、マルセロ4404セレブリティおよびゲスト出演
More news about: Consumer Technology Association
Jan 05, 2026, 16:03 ET Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is
More news about: Viking Therapeutics, Inc.
Jan 05, 2026, 11:50 ET Get a Jump Start on 2026 Health Goals with "New Year, New You" Sale at FSA Store® and HSA Store®
account (FSA) and health savings account (HSA) funds by offering discounts on eligible telehealth services, including mental health counseling, GLP-1 medications, vision care, oral health, and wearable health technologyDALLAS, Jan.
More news about: Health-E Commerce
Jan 05, 2026, 09:00 ET MEL ROBBINS LAUNCHES PURE GENIUS PROTEIN: A POCKET-SIZED 23 GRAM PROTEIN SHOT DESIGNED FOR BUSY PEOPLE
Salas-Whalen, MD, a board-certified endocrinologist, obesity medicine specialist, and bestselling author of Weightless: A Doctor's Guide to GLP-1 Medications."This isn't about chasing a trend," says Robbins. "It's about making it easier for people to prioritize their health, particularly
More news about: Pure Genius Protein
Jan 05, 2026, 09:00 ET Withings Redefines Preventive Health with Body Scan 2, the World's First Science-Backed Longevity Station
cardiometabolic balance: chronic stress, sedentary routines, midlife visceral and abdominal fat gain, perimenopause and menopause, athletic training, or GLP-1 weight-loss treatments where muscle preservation is essential.Premium Design, Built for Everyday UseBody Scan 2 combines a
More news about: Withings
Jan 05, 2026, 08:30 ET MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
(OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR),
More news about: MetaVia Inc.
Jan 05, 2026, 08:05 ET RO LAUNCHES WEGOVY® PILL THROUGH INTEGRATION WITH NOVO NORDISK
Ro to play critical role in ensuring patients nationwide get access to first and only oral GLP-1 weight loss medication at the lowest available cash priceNEW YORK, Jan. 5, 2026 /PRNewswire/
More news about: Ro
Jan 05, 2026, 08:00 ET Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
2026 /PRNewswire/ -- Wegovy® pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill for the first time. This advancement opens new possibilities for the more than 100 million Americans living with obesity.2
More news about: NOVO NORDISK INC.
Jan 05, 2026, 07:45 ET Pipe17 Caps 2025 with 163% Order Volume Growth, Industry-First AI Innovations, and Leadership in Open Commerce Standards
Platform that unifies orders, inventory, products and fulfillments across commerce channels, marketplaces, ERPs and fulfillment partners. Backed by GLP Capital, LFX Ventures, and Blumberg Capital, Pipe17 helps innovative brands like Allbirds, Wyze and MaryRuth's, and leading 3PLs like FedEx, Radial,
More news about: Pipe17
Jan 05, 2026, 07:00 ET RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
once-daily oral therapy for GLP-1/GIP receptor agonist therapy-associated GI side effects. Phase 2 Proof-of-Concept study designed, and intellectual property expanded-->2% of Americans take GLP-1 receptor agonist drugs4
More news about: RedHill Biopharma Ltd.
Jan 05, 2026, 07:00 ET Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
co-formulate nimacimab with ENHANZE gives us a validated approach to evaluate multiple dose-ranging strategies, including in combination with GLP-1 receptor agonists."Skye will make milestone payments tied to the achievement of certain development and commercialization events. Halozyme
More news about: Halozyme Therapeutics, Inc.
Jan 05, 2026, 05:09 ET O QUE VOCÊ NÃO PODE PERDER NA CES 2026
IA masculina padrão, apresentado pela K'ept Health6 de janeiro, 9h55, Venetian, Marcello 4404O efeito GLP-1: mulheres moldando o futuro da saúde, apresentado pela PwC 6 de janeiro, 10h50, Venetian, Marcello 4404Celebridades
More news about: Consumer Technology Association
Jan 05, 2026, 04:56 ET LO QUE NO SE PUEDE PERDER EN EL CES 2026
masculina por defecto, presentada por K'ept Health6 de enero, 9:55 a. m., Venetian, Marcello 4404El efecto GLP-1: Mujeres que moldean el futuro de la salud, presentada por PwC 6 de enero, 10:50 a. m., Venetian, Marcello 4404Apariciones
More news about: Consumer Technology Association
Jan 04, 2026, 19:10 ET Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
the first quarter of 2026. Ascletis recently completed its 13-week Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of obesity (NCT07002905)
More news about: Ascletis Pharma Inc.
Jan 04, 2026, 19:10 ET 歌禮宣佈其口服小分子GLP-1，ASC30，在糖尿病受試者中的13周II期研究IND獲美國FDA批准
View original content:https://www.prnewswire.com/apac/zh/news-releases/glp-1asc3013iiindfda-302652106.htmlSOURCE 歌禮製藥有限公司
More news about: 歌禮製藥有限公司